{"id":"W4415941891","doi":"10.1016/j.annonc.2025.08.2101","title":"1471MO Adding ipilimumab (IPI) to atezolizumab (ATEZO) plus bevacizumab (BEV) in patients (pts) with unresectable hepatocellular carcinoma (uHCC) in first-line systemic therapy (1L): PRODIGE 81/FFCD 2101 - TRIPLET HCC","year":2025,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Hepatocellular Carcinoma Treatment and Prognosis","field":"Medicine","cited_by":1,"is_retracted":false,"has_abstract":false,"ca_institutions":"Hotel Dieu Hospital","funders":"","keywords":"Atezolizumab; Ipilimumab; Bevacizumab; Systemic therapy; Hepatocellular carcinoma; Nivolumab; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003129498,0.0002461512,0.0007332367,0.000205125,0.0001582081,0.000419765,0.0001941961,0.0002561918,0.003155753],"category_scores_gemma":[0.000466667,0.0001358648,0.0006052811,0.0001952827,0.0001589853,0.0003070391,0.0001904021,0.000726832,0.0004725104],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005555935,"about_ca_system_score_gemma":0.0005860323,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0009034257,"about_ca_topic_score_gemma":0.003544945,"domain_scores_codex":[0.9998714,0.00003394366,0.0000123547,0.0000238138,0.00001394813,0.0000445315],"domain_scores_gemma":[0.9998749,0.00002029866,0.00002117937,0.00000858364,0.000007862935,0.00006710793],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.2360093,0.006595202,0.09252426,0.0007855261,0.001323151,0.001013236,0.0002531121,0.003658789,0.04293399,0.0006253536,0.01195063,0.6023275],"study_design_scores_gemma":[0.07717812,0.354182,0.4824685,0.0004271743,0.003965841,0.004113969,0.000324691,0.009866959,0.03137571,0.0008509765,0.03514102,0.0001050166],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9946172,0.001719499,0.0001790374,0.0003683076,0.0001380337,0.0001002846,0.0002881744,0.00005570353,0.002533938],"genre_scores_gemma":[0.9967129,0.0006719312,0.0003611459,0.0002123692,0.00006758182,0.00006172132,0.0006263076,0.000006907903,0.001279085],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003155753,"threshold_uncertainty_score":0.01055712,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08403274616397495,"score_gpt":0.3161995178664331,"score_spread":0.2321667717024581,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}